Company / Cash & Equivalents
Janux Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$52.3M
FY2025
5-year range
$19.2M / $430.6M
FY2021-FY2025
Trend
-87.8%
vs FY2024
Sector context
#180 of 209
Health Care
What the data says
Janux Therapeutics, Inc.'s cash & equivalents of $52M is lower than 86% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 6 years, ranging from $8M in FY2020 to $431M in FY2024.
Based on SEC 10-K filings.
$52M in FY2025 with a 5-year CAGR of +46.3%.
Improved from $19M to $52M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- +46.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 14% in Health CareTop 86% of 209This company $52.3M Sector average $696.0M
▼
-92.5% below sector average
Key checks
Key Insights
- 5-year CAGR of +46.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 87.8% year-over-year.
- Ranks #180 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 9.17 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $52.3M | -87.8% |
| FY2024 | $430.6M | +2142.2% |
| FY2023 | $19.2M | -62.7% |
| FY2022 | $51.4M | +44.5% |
| FY2021 | $35.6M | +355.4% |
| FY2020 | $7.8M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026